Bone Fracture Risk is Not Associated with the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Cohort Analysis
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605520968 | ||
| 003 | CHVBK | ||
| 005 | 20210128100738.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150801xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s00223-015-9993-5 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s00223-015-9993-5 | ||
| 245 | 0 | 0 | |a Bone Fracture Risk is Not Associated with the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Population-Based Cohort Analysis |h [Elektronische Daten] |c [Johanna Driessen, Ronald Henry, Hein van Onzenoort, Arief Lalmohamed, Andrea Burden, Daniel Prieto-Alhambra, Cees Neef, Hubert Leufkens, Frank de Vries] |
| 520 | 3 | |a Glucagon-like Peptide-1 receptor agonists (GLP1-ra) are a relatively new class of anti-hyperglycemic drugs which may positively affect bone metabolism and thereby decrease (osteoporotic) bone fracture risk. Data on the effect of GLP1-ra on fracture risk are scarce and limited to clinical trial data only. The aim of this study was to investigate, in a population-based cohort, the association between the use of GLP1-ra and bone fracture risk. We conducted a population-based cohort study, with the use of data from the Clinical Practice Research Datalink (CPRD) database (2007-2012). The study population (N=216,816) consisted of all individuals with type 2 diabetes patients with at least one prescription for a non-insulin anti-diabetic drug and were over 18years of age. Cox proportional hazards models were used to estimate the hazard ratio of fracture in GLP1-ra users versus never-GLP1-ra users. Time-dependent adjustments were made for age, sex, lifestyle, comorbidity and the use of other drugs. There was no decreased risk of fracture with current use of GLP1-ra compared to never-GLP1-ra use (adjusted HR 0.99, 95% CI 0.82-1.19). Osteoporotic fracture risk was also not decreased by current GLP1-ra use (adjusted HR 0.97; 95% CI 0.72-1.32). In addition, stratification according to cumulative dose did not show a decreased bone fracture risk with increasing cumulative GLP1-ra dose. We showed in a population-based cohort study that GLP1-ra use is not associated with a decreased bone fracture risk compared to users of other anti-hyperglycemic drugs. Future research is needed to elucidate the potential working mechanisms of GLP1-ra on bone. | |
| 540 | |a The Author(s), 2015 | ||
| 690 | 7 | |a GLP1-ra |2 nationallicence | |
| 690 | 7 | |a Fracture |2 nationallicence | |
| 690 | 7 | |a Diabetes mellitus type 2 |2 nationallicence | |
| 690 | 7 | |a Cohort study |2 nationallicence | |
| 690 | 7 | |a CPRD |2 nationallicence | |
| 700 | 1 | |a Driessen |D Johanna |u Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands |4 aut | |
| 700 | 1 | |a Henry |D Ronald |u Department of Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands |4 aut | |
| 700 | 1 | |a van Onzenoort |D Hein |u Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands |4 aut | |
| 700 | 1 | |a Lalmohamed |D Arief |u Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands |4 aut | |
| 700 | 1 | |a Burden |D Andrea |u Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands |4 aut | |
| 700 | 1 | |a Prieto-Alhambra |D Daniel |u Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK |4 aut | |
| 700 | 1 | |a Neef |D Cees |u Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands |4 aut | |
| 700 | 1 | |a Leufkens |D Hubert |u Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands |4 aut | |
| 700 | 1 | |a de Vries |D Frank |u Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands |4 aut | |
| 773 | 0 | |t Calcified Tissue International |d Springer US; http://www.springer-ny.com |g 97/2(2015-08-01), 104-112 |x 0171-967X |q 97:2<104 |1 2015 |2 97 |o 223 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00223-015-9993-5 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s00223-015-9993-5 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Driessen |D Johanna |u Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Henry |D Ronald |u Department of Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a van Onzenoort |D Hein |u Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre+, Maastricht, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Lalmohamed |D Arief |u Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Burden |D Andrea |u Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Prieto-Alhambra |D Daniel |u Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Neef |D Cees |u Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Leufkens |D Hubert |u Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a de Vries |D Frank |u Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Calcified Tissue International |d Springer US; http://www.springer-ny.com |g 97/2(2015-08-01), 104-112 |x 0171-967X |q 97:2<104 |1 2015 |2 97 |o 223 | ||